Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

PURPOSE Multiple myeloma (MM) is accompanied by heterogeneous somatic alterations. The overall goal of this study was to describe the genomic landscape of myeloma using deep whole-genome sequencing (WGS) and develop a model that identifies patients with long survival. METHODS We analyzed deep WGS data from 183 newly diagnosed patients with MM treated with lenalidomide, bortezomib, and dexamethasone (RVD) alone or RVD + autologous stem cell transplant (ASCT) in the IFM/DFCI 2009 study (ClinicalTrials.gov identifier: NCT01191060). We integrated genomic markers with clinical data. RESULTS We report significant variability in mutational load and processes within MM subgroups. The timeline of observed activation of mutational processes provides the basis for 2 distinct models of acquisition of mutational changes detected at the time of diagnosis of myeloma. Virtually all MM subgroups have activated DNA repair–associated signature as a prominent late mutational process, whereas APOBEC signature targeting C>G is activated in the intermediate phase of disease progression in high-risk MM. Importantly, we identify a genomically defined MM subgroup (17% of newly diagnosed patients) with low DNA damage (low genomic scar score with chromosome 9 gain) and a superior outcome (100% overall survival at 69 months), which was validated in a large independent cohort. This subgroup allowed us to distinguish patients with low- and high-risk hyperdiploid MM and identify patients with prolongation of progression-free survival. Genomic characteristics of this subgroup included lower mutational load with significant contribution from age-related mutations as well as frequent NRAS mutation. Surprisingly, their overall survival was independent of International Staging System and minimal residual disease status. CONCLUSION This is a comprehensive study identifying genomic markers of a good-risk group with prolonged survival. Identification of this patient subgroup will affect future therapeutic algorithms and research planning.

[1]  Mathieu Lupien,et al.  Candidate Cancer Driver Mutations in Distal Regulatory Elements and Long-Range Chromatin Interaction Networks. , 2020, Molecular cell.

[2]  G. Morgan,et al.  Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma , 2019, Leukemia.

[3]  M. Mansour,et al.  The role of noncoding mutations in blood cancers , 2019, Disease Models & Mechanisms.

[4]  R. Houlston,et al.  Mutational processes contributing to the development of multiple myeloma , 2019, Blood Cancer Journal.

[5]  O. Decaux,et al.  Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Auclair,et al.  Multiple myeloma immunoglobulin lambda translocations portend poor prognosis , 2019, Nature Communications.

[7]  Nofisat Ismaila,et al.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Parmigiani,et al.  Deciphering the chronology of copy number alterations in Multiple Myeloma , 2019, Blood Cancer Journal.

[9]  A. Gonzalez-Perez,et al.  Local Determinants of the Mutational Landscape of the Human Genome , 2019, Cell.

[10]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[11]  P. Campbell,et al.  Genomic patterns of progression in smoldering multiple myeloma , 2018, Nature Communications.

[12]  H. Goldschmidt,et al.  Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. , 2018, Blood.

[13]  B. Gloss,et al.  Realizing the significance of noncoding functionality in clinical genomics , 2018, Experimental & Molecular Medicine.

[14]  Pingping Qu,et al.  A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis , 2018, Leukemia.

[15]  Nicolai J. Birkbak,et al.  Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer , 2018, npj Breast Cancer.

[16]  N. Bolli,et al.  Multiple myeloma clonal evolution in homogeneously treated patients , 2018, Leukemia.

[17]  H. Avet-Loiseau,et al.  Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[18]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[19]  Justin K. Huang,et al.  A global transcriptional network connecting noncoding mutations to changes in tumor gene expression , 2018, Nature Genetics.

[20]  Giovanni Parmigiani,et al.  Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma , 2018, Leukemia.

[21]  E. Pinatel,et al.  Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines , 2017, Leukemia.

[22]  Y. Asmann,et al.  High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma , 2017, Blood Cancer Journal.

[23]  Nicholas A. Sinnott-Armstrong,et al.  Pan-cancer screen for mutations in non-coding elements with conservation and cancer specificity reveals correlations with expression and survival , 2017, npj Genomic Medicine.

[24]  Icgc,et al.  Pan-cancer analysis of whole genomes , 2017, bioRxiv.

[25]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[26]  D. Landau,et al.  Genomic complexity of multiple myeloma and its clinical implications , 2017, Nature Reviews Clinical Oncology.

[27]  Rafael Rosales,et al.  signeR: an empirical Bayesian approach to mutational signature discovery , 2017, Bioinform..

[28]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[29]  V. Seshan,et al.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing , 2016, Nucleic acids research.

[30]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[31]  Xiaoyu Chen,et al.  Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications , 2016, Bioinform..

[32]  D. Hose,et al.  Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma , 2016, Haematologica.

[33]  Scott W. Piraino,et al.  Beyond the exome: the role of non-coding somatic mutations in cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Gerstein,et al.  Role of non-coding sequence variants in cancer , 2016, Nature Reviews Genetics.

[35]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  N. Munshi,et al.  Genomic heterogeneity in multiple myeloma. , 2015, Current opinion in genetics & development.

[37]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[38]  J. Keats,et al.  Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma , 2014, Leukemia.

[39]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[40]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[41]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.

[42]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[43]  N. Munshi,et al.  Genomics of Multiple Myeloma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[45]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.